GSK information hub: Initial maintenance therapy in COPD (contains brand information)
Content funded and provided by GSK
For healthcare professionals only
Prescribing information is available via a link at the bottom of the page
Choosing an initial maintenance therapy for COPD patients
LAMA/LABAs are indicated as maintenance bronchodilator treatments to relieve symptoms in adult patients with COPD.
What does NICE recommend?
NICE updated its COPD guideline (in Dec 2018) to recommend LAMA/LABA as initial maintenance therapy in patients with no asthmatic features/features suggesting steroid responsiveness who remain breathless/have exacerbations despite short acting bronchodilator therapy.1
According to the guidance, such patients should have spirometrically confirmed COPD as well as have been offered/received treatment for tobacco dependence (if smokers), had optimised non-pharmacological management and received relevant vaccinations.1
3 key reasons:
The NICE guidelines state that ‘the evidence showed that, compared with other dual therapy combinations and monotherapy, LAMA+LABA’:1
‘provides the greatest benefit to overall quality of life’1
‘is better than other inhaled treatments for many individual outcomes…’1
GSK organised and funded a roundtable meeting with respiratory experts to discuss the health-system impact of LAMA/LABA initial maintenance therapy (IMT) in COPD. Attendees were paid an honorarium for their time by GSK. Watch the video to understand why you might want to consider LAMA/LABA initial maintenance therapy (IMT) in specific COPD patients.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow card in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
COPD in over 16s: diagnosis and management NICE guideline [NG115] Published date: July 2019. Accessed: June 2020.
Maleki-Yazdi M et al. Adv Ther 2016; 33:2188–2199
GSK data on file RF/UCV/0112/15
Maleki-Yazdi MR et al. Respir Med 2014;108:1752–1760
This link takes you to a third party website that is part of the Bristol-Myers Squibb Group and Pfizer Group. The Alliance (Bristol Myers Squibb Group and Pfizer Group) recommends that you check whether it is suitable for you as per its intended audience and the applicable laws and regulations before accessing it. If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.